What does Oculus Innovative Sciences do? We have developed, and manufacture and market, a family of products with developmental formulations intended to help prevent and treat infections in chronic and acute wounds. Infection is a serious potential complication in both chronic and acute wounds, and controlling infection is a critical step in wound healing. Our flag ship product, Microcyn, is a non-toxic, electrically charged, or oxychlorine, water-based solution that is designed to treat a wide range of organisms that cause disease, or pathogens, including viruses, fungi, spores and antibiotic resistant strains of bacteria, such as Methicillin-resistant Staphylococcus aureus, or MRSA, and Vancomycin-resistant Enterococcus, or VRE, in solution. Microcyn has received CE Mark, or European Union certification, for wound cleaning and reduction of microbial load, three U.S. Food and Drug Administration, or FDA, 510(k) clearances as a medical device in wound cleaning, or debridement, lubricating, moistening and dressing. Microcyn has also been granted approvals for use as an antiseptic, disinfectant and sterilant in Mexico and approval for use in cleaning and debriding in wound management in India. We do not have the necessary regulatory approvals to market Microcyn in the United States as a drug, nor do we have regulatory clearance or approval to market Microcyn in the U.S. as a medical device for a wound healing indication.
Who are Oculus Innovative Science customers? This depends in large part on which part of the world you're in. In the United States, it is currently a mix of podiatrists, wound care doctors/nurses, and individuals who are using Microcyn Wound Care for moistening absorbent wound dressings and for debriding and cleaning acute and chronic dermal lesions, such as stage I-IV pressure ulcers, stasis ulcers, diabetic ulcers, burns, abrasions and minor irritations of the skin. Secondarily, U.S. veterinarians, horse trainers/owners and companion pet owners use the Vetericyn Wound Spray for Animals (formulated with Microcyn) to help debride, rinse, and eliminate odors in a wide variety of wounds, ulcers and abrasions. In the European Union, Microcyn Wound Care is intended for use by podiatrists, wound care doctors/nurses and individuals for use in the debridement, irrigation and moistening of acute and chronic wounds, ulcers, cuts, abrasions and burns.
In Mexico, Microcyn60 (formulated with Microcyn) has been approved by the Mexican Ministry of Health as a disinfectant, antiseptic and sterilant for use by surgeons, doctors, podiatrists and patients for the treatment of complex wounds, such as burns and diabetic foot ulcers.
Other customers include partners or licensees who may come under agreement to package and market Microcyn Technology via private label such is the case in India, where Alkem Laboratories is distributing a wound care product under the brand name of Oxum.
When was Oculus Innovative Sciences founded? We were incorporated in California in 1999 as Micromed Laboratories, Inc. In August 2001, we changed our name to Oculus Innovative Sciences, Inc. In December 2006, we reincorporated in Delaware.
Where is Oculus located? Our principal executive offices are located at:
1129 N. McDowell Blvd. Petaluma, California 94954
and our telephone number is (707) 782-0792.
We have two principal subsidiaries: Oculus Technologies of Mexico, S.A. de C.V., organized in Mexico, and Oculus Innovative Sciences Netherlands, B.V., organized in The Netherlands.
How many employees does Oculus have? As of January 2007, 76 full-time employees globally.
When was Oculus Innovative Sciences' initial public offering, and what was the offering price? Oculus Innovative Sciences, Inc. went public on January 25, 2007 and the offering price was $8.00 per share.
What is the company's CUSIP number? Oculus' CUSIP number is 67575P10
What is Oculus' stock symbol and on what stock exchange is it listed? Oculus' stock symbol is OCLS and is listed on the Nasdaq Global Market system.
Which analysts currently follow the company? Oculus Innovative Sciences is currently followed by Mark Taylor (Roth Capital Partners) and Ding Ding (Maxim Group).
The above may not be a complete list of brokerage firms or analysts following our common stock, and this list is subject to change. Any opinions, estimates, forecasts or predictions regarding Oculus' historical or projected performance made by analysts are theirs alone and do not represent the opinions, estimates, forecasts or predictions of Oculus' or its management. We are providing this information as a service to our stockholders, and the inclusion of this list on our website does not imply our endorsement of or concurrence with any information, conclusions or recommendations in the analysts' reports. We do not distribute analysts' reports. Some of the firms listed above may be market-makers in our stock or hold long or short positions in our stock, and may provide services to us for which they are compensated.
When is Oculus' fiscal quarter and year-end dates? Oculus operates on a fiscal year ending March 31st. Our quarterly reporting periods end on June 30th, September 30th, December 31st and March 31st.
Who is Oculus' transfer agent and how does a registered shareholder contact the agent regarding account information? Oculus' transfer agent is:
If I own certificated shares of Oculus and have misplaced my stock certificate, what can I do? You can contact Oculus' transfer agent, Mellon Investor Services LLC.
I've recently moved. How do I submit my new address? You must contact our transfer agent, Mellon Investor Services LLC.
Who are the auditors of Oculus Innovative Sciences? Marcum & Kliegman LLP, New York, New York
Who is the company's outside legal counsel? Pillsbury Winthrop Shaw Pittman LLP 2475 Hanover Street Palo Alto, CA 94304-1114
Does Oculus currently offer a direct stock purchase plan? The company does not offer a direct stock purchase program.
Does Oculus pay a cash dividend on its shares of common stock? We have never paid our stockholders cash dividends, and we do not anticipate paying any cash dividends in the foreseeable future as we intend to retain any earnings for use in our business.
Who are the Oculus Officers & Directors? Oculus's officers and directors can be found on the Corporate Governance page of the investor relations Web site.
How can I contact someone at Oculus with a question or request? Please visit the Contact Us page on the Company website. Email addresses for specific questions and concerns are provided. Additionally, Oculus can be reached by calling 707-782-0792.
How can I find information on Oculus's SEC filings? Oculus's SEC filings can be obtained by visiting SEC Filings page or www. sec.gov.
Who handles investor relations for Oculus? The Ruth Group is Oculus' investor relations agency of record. For additional information, please contact Sara Ephraim at 646-536-7002 or
sephraim@theruthgroup.com
